Ian Smith is a biotechnology leader with more than 20 years of finance and operations experience. In addition to serving as an advisor and member of the Board of Directors of Foghorn Therapeutics, Ian serves as a senior advisor to Bain Capital Life Sciences, chair of the board of Solid Biosciences, gene therapy for DMD, executive chair of Viacyte Inc, cell therapy for diabetes, board member to AavantiBio, gene therapy for Freidricks Ataxia and provides advisory and consulting services to these and other biotechnology companies.
Prior to his current roles he was executive vice president and chief operating officer of Vertex Pharmaceuticals Inc. as well as chief financial officer between 2001 and 2019. Prior to 2001, Mr. Smith was a partner in the Life Science and Technology Practice of the accounting firm Ernst & Young LLP.
Ian received a B.A. with honors in accounting and finance from Manchester Metropolitan (UK).